Home>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>7,8-Dihydroxyflavone

7,8-Dihydroxyflavone (Synonyms: 7,8-DHF)

Catalog No.GC16853

Tyrosine kinase receptor B (TrkB) agonist

Products are for research use only. Not for human use. We do not sell to patients.

7,8-Dihydroxyflavone Chemical Structure

Cas No.: 38183-03-8

Size Price Stock Qty
10mM (in 1mL DMSO)
$50.00
In stock
10mg
$131.00
In stock
50mg
$74.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

7,8-Dihydroxyflavone is a potent and selective TrkB agonist that mimics the physiological actions of Brain-derived neurotrophic factor (BDNF). Displays therapeutic efficacy toward various neurological diseases[1].

7,8-Dihydroxyflavone (500 nM) protects the primary cortical neurons and locus coeruleus (LC) neurons from Aβ-induced toxicity and promotes dendritic growth and synaptogenesis[1].

7,8-Dihydroxyflavone (5 mg/kg/day) prevents synaptic loss and memory deficits in a mouse model of Alzheimer’s Disease[1]. Administration of 7,8- dihydroxyflavone to mice activates TrkB in the brain, inhibits kainic acid-induced toxicity, decreases infarct volumes in stroke in a TrkBdependent manner, and is neuroprotective in an animal model of Parkinson disease[2].

References:
[1]. Zhang Z, et al. 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 2014 Feb;39(3):638-50.

Reviews

Review for 7,8-Dihydroxyflavone

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 7,8-Dihydroxyflavone

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.